CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

Completed · Phase 1

Conditions studied: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.

Key facts

Study ID

NCT00031941

Run by

National Institutes of Health Clinical Center (CC)

Starts

2002-04-01

Expected to finish

2009-04-01

Last updated by the study team

2012-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
• NCI - Center for Cancer Research — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.